Press ESC to close

Peptide Lab App Log in Articles News Guide Products
More Peptide Tracker Calculator Best Calculators Peptide Statistics Contact Newsletter
Français English Deutsch Español Português العربية Italiano Polski 한국어 日本語 中文 Русский Nederlands Čeština Svenska Türkçe
Regulation Malaysia

Malaysia's health ministry says GLP-1 treatment still has no dedicated allocation

Malaysia's Ministry of Health (KKM) will keep working to obtain a dedicated allocation to widen access to GLP-1 treatment with drugs such as Ozempic and Mounjaro, Health Minister Datuk Seri Dr Dzulkefly Ahmad said in Parliament, in remarks reported on 2 November 2026.

Rows of medicine boxes and vials on a hospital pharmacy shelf

What is GLP-1?

GLP-1 is a 30-amino-acid gut hormone released after meals; it increases insulin and lowers glucagon only when glucose is high, slows gastric emptying and reduces appetite through receptors in the brain.

Read the full guide →

In 30 seconds

  • 240 applications for treatment with these drugs were approved for the period January to September 2026, at a total cost of RM2.56 million through the ministry's existing allocation.
  • The ministry has submitted a request but so far has not received a dedicated allocation, and is still using its existing allocation.
  • In his remarks, the minister said SGLT2 inhibitors, whose cost he described as somewhat lower than drugs from the GLP-1 receptor agonist group, can be considered in particular for patients who do not have obesity but have comorbidities such as heart disease and chronic kidney disease.

Why it matters

Access to GLP-1 treatment in Malaysia's public system currently depends on money the Ministry of Health already has, not on a line set aside for it. Health Minister Datuk Seri Dr Dzulkefly Ahmad said 240 applications for treatment with these drugs were approved for the period January to September 2026, at a total cost of RM2.56 million through the ministry's existing allocation. He said the ministry has submitted a request, has so far not received a dedicated allocation, and will continue to work to obtain one for GLP-1 treatment in the future.

The details

  • The ministry says it will keep working to obtain a dedicated allocation to expand access to GLP-1 treatment with drugs such as Ozempic and Mounjaro, especially for obesity and diabetes patients who need it.
  • Approved applications: 240 for January to September 2026, for a total cost of RM2.56 million, from the ministry's existing allocation.
  • Health Minister Datuk Seri Dr Dzulkefly Ahmad said: "GLP-1 requires a larger allocation. We have submitted an application, but so far have not received a dedicated allocation and are still using the existing allocation."
  • He also pointed to another group of drugs, SGLT2 inhibitors, which he said can be considered in particular for patients who do not have obesity but have comorbidities such as heart disease and chronic kidney disease (CKD), and whose cost is somewhat lower than drugs from the GLP-1 receptor agonist group.
  • "Therefore, we will consider all these treatment options based on the needs and clinical condition of the patient," he said in Parliament.
  • The minister stressed that obesity management cannot depend on the use of medicines alone and needs a comprehensive approach adapted to each patient's health condition, covering lifestyle change, healthy eating practices, physical activity, meal replacement therapy and bariatric surgery for patients who meet the clinical indications.
  • The ministry runs the Multidisciplinary Integrated Management of Obesity (MIMO) programme at 33 health clinics, with specialist support at 13 hospitals.

What it does not change

This is a funding statement, not a regulatory decision: nothing in the minister's remarks approves, registers or withdraws any product. According to the minister, the ministry is still using its existing allocation rather than a dedicated one. His position is also that medicines are only one part of obesity management, alongside lifestyle change, healthy eating, physical activity, meal replacement therapy and bariatric surgery for patients who meet the clinical indications.

What's next

The ministry says it will continue to work to obtain an allocation for GLP-1 treatment in the future. In the meantime, the minister said all treatment options will be considered based on the needs and clinical condition of the patient, with SGLT2 inhibitors available as an option to consider in particular for patients without obesity who have comorbidities such as heart disease and chronic kidney disease. The MIMO programme continues at 33 health clinics with specialist support at 13 hospitals.

What we don't know yet

The source does not say how large an allocation the ministry asked for, when a decision on that request might come, or what would happen to the approval rate if a dedicated allocation were granted. It does not give the number of applications submitted or refused, the criteria used to approve them, which conditions the approved patients had, or any figures after September 2026.

Products sold online as research peptides are not the medicines studied or approved in this news. A medicine is available in a country only after that country's medicines agency approves it.

Source documents

This article reports news for information only. It is not medical or legal advice and does not recommend any use or dose. Every fact comes from the source documents listed above.